News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

15

July

2025

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Read More
3

July

2025

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for AUD at Tel Aviv Sourasky Medical Centre
Read More
30

June

2025

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for AUD
Read More
27

June

2025

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
Read More
23

June

2025

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Read More
12

June

2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
Read More
5

June

2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
Read More
12

May

2025

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
Read More
25

April

2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Read More
23

April

2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
Read More
21

April

2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Read More
17

April

2025

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Read More
10

April

2025

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Read More
8

April

2025

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds
Read More
1

April

2025

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Read More